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Ca2dependent contraction by the saponoside
escin in rat vena cava: Implications in venotonic
treatment of varicose veins
Joseph D. Raffetto, MD,a,b and Raouf A. Khalil, MD, PhD,a Boston and West Roxbury, Mass
Background: Saponosides (horse chestnut seed extract, escin) and flavonoids (diosmin, Daflon 500, Servier, France)
exhibit venotonic properties that have been utilized in treatment of varicose veins. However, the cellular mechanisms
underlying the venotonic properties of escin and diosmin are unclear. Because Ca2 is a major regulator of venous smooth
muscle (VSM) function, we tested the hypothesis that escin and diosmin promote Ca2dependent venous contraction.
Methods: Rings of inferior vena cava (IVC) from male rats were suspended in a tissue bath for measurement of isometric
contraction. Following control contraction to 96 mM KCl, the effects of escin and diosmin (1010 to 104 M) on vein
contraction were measured. To test the role of intracellular Ca2 release, the vein response to escin and diosmin was
measured in Ca2free (2mM EGTA) Krebs. To test for Ca2dependent effects, IVC segments were pretreated with
escin or diosmin (104 M) in 0 Ca2 Krebs, then extracellular CaCl2 (0.1, 0.3, 0.6, 1, 2.5 mM) was added and the
[Ca2]econtraction relationship was constructed. To test for synergistic effects of diosmin, IVC segments were
pretreated with diosmin (104 M), then stimulated with KCl (16-96 mM) or escin (1010 to 104 M) and vein
contraction was measured. Contraction data were presented as mg/mg tissue (means  SEM).
Results: In IVC segments incubated in normal Krebs (2.5 mM Ca2), escin caused concentration-dependent contraction
(max 104.3  19.6 at 104 M). Escin-induced contraction was not a rigor state, because after washing with Krebs, the
veins returned to a relaxed state. In Ca2free Krebs, there was essentially no contraction to escin. In escin-treated veins
incubated in 0 Ca2 Krebs, stepwise addition of extracellular CaCl2 caused corresponding increases in contraction (max
80.0 11.1 at 2.5 mM). In the absence of escin, the -adrenergic agonist phenylephrine (PHE, 105 M), angiotensin II
(AngII, 106 M), and membrane depolarization by KCl (96 mM) caused significant contraction (122.5 45.1, 114.2
12.2 and 221.7  35.4, respectively). In IVC segments pretreated with escin (104 M), the contractile response to PHE
(9.7  2.6), AngII (36.0  9.1), and KCl (82.3  10.2) was significantly reduced. Diosmin (104 M) caused small
contractions in normal Krebs (11.7  1.9) and Ca2free Krebs (4.2  2.2). In diosmin-treated veins incubated in 0
Ca2 Krebs, addition of extracellular CaCl2 caused minimal contraction. Diosmin did not enhance the IVC contraction
to PHE, AngII, or escin, but enhanced the contractile response to KCl (24-51 mM).
Conclusion: In rat IVC, escin induces extracellular Ca2dependent contraction, but disrupts -adrenergic and AT1R
receptor-mediated pathways and depolarization-induced contraction. The initial venotonic benefits of escin may be offset
by disruption of vein response to endogenous venoconstrictors, limiting its long-term therapeutic benefits in varicose
veins. Diosmin does not cause venous contraction or potentiate the venotonic effects of endogenous venoconstrictors or
escin ex vivo, and its use as venotonic may need to be further evaluated. (J Vasc Surg 2011;54:489-96.)
Clinical Relevance:Venotonic agents are used in clinical practice for treatment of varicose veins. Saponosides such as escin
(horse chestnut seed extract) and flavonoids such as disomin (active ingredient in Daflon 500, Servier, France) are
commonly prescribed venotonic agents. Although escin is known to form pores in the plasma membrane, the mechanisms
of its venotonic action are less clear. Also, while diosmin may affect the venous tissue inflammatory response and
lymphatic drainage, its direct effects on vein function have not been fully examined. The present results suggest that escin
has significant Ca2dependent venotonic effects but also reduces the effects of endogenous venoconstrictors, which
could limit its long-term therapeutic benefits in varicose veins. Disomin has negligible direct venotonic effects and does
not potentiate the effects of endogenous venoconstrictors or escin, and its use as a venotonic agent may need further
evaluation.
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August 2011490 Raffetto and KhalilVaricose veins is a common disease of the lower extrem-
ity characterized by vein valve dysfunction, vein dilation,
and tortuosity.1-3 If untreated, varicose veins can progress
causing severe venous insufficiency and may lead to signif-
icant pain, venous thrombophlebitis, and lower extremity
skin unlceration.1,4-6 Surgical treatment approaches of var-
icose veins include vein ablation and stripping. Other more
conservative treatment strategies to reduce the pain and
edema associated with varicose veins include compression
stockings and oral venotonic medication.7,8
Saponosides such as horse chestnut seed extract (Aes-
culus hippocastanum, Aescin, Escin, -escin) and fla-
vonoids such as diosmin (Daflon 500, Servier, France)
exhibit venotonic properties that have been utilized in
treatment of chronic venous disorders, including varicose
veins and lower extremity venous ulcers.9-11 Escin is also
used clinically to treat edema, pain, leg fatigue/heaviness,
calf cramps, and itching.12,13 Some of the suggested mech-
anisms of venotonic action of escin include increasing en-
dothelial cell permeability to Ca2 and the release of vaso-
constrictor prostanoids such as prostaglandin F2, and
sensitization of the vein wall to the contractile effects of
serotonin and histamine.10,14,15 Escin also forms small
pores in the cell membrane and has been used as a pharma-
cologic tool to assess the sensitivity of the contractile mech-
anisms of blood vessels to different agonists10,16 and for
permeabilization of vascular smooth muscle (VSM) mem-
branes and manipulation of intracellular ionic environment
and regulatory proteins.15,17 The escin-induced pores in
the plasma membrane permit Ca2 to diffuse freely across,
and make the cell membrane permeable to higher molecu-
lar weight solutes (3000) of biological interest, such as
heparin and calmodulin, yet retain coupled receptors.18 On
the other hand, diosmin has been suggested to decrease the
vein tissue inflammatory response, increase lymph drainage, and
to inhibit venous catechol-Omethyltransferase (COMT) and
thereby decreases the metabolism of norepinephrine and
prolongs its venoconstrictor effects.19,20 Another study
has shown that diosmin enhances the effects of other
venotonics such as escin.16 However, the cellular mech-
anisms underlying the venotonic properties of escin and
diosmin have not been clearly established. Also, the
direct effects of escin and diosmin on vein tissue function
and their synergistic effects with each other and with
other endogenous venoconstrictors have not been fully
examined. Because Ca2 is a major regulator of VSM
function,21 we tested the hypothesis that escin promotes
Ca2dependent mechanisms of venous contraction
and that diosmin potentiates these mechanisms.
METHODS
Solutions, drugs and chemicals. Normal Krebs solu-
tion contained in mM: NaCl 120, KCl 5.9, NaHCO3 25,
NaH2PO4 1.2, dextrose 11.5 (Fisher Scientific, Fair Lawn,
NJ), CaCl2 2.5 (BDH Laboratory Supplies, Poole, Eng-
land), MgCl2 1.2 (Sigma, St. Louis, Mo). Krebs solution
was bubbled with 95% O and 5% CO for 30 to 452 2
minutes, at an adjusted pH 7.4. For nominally 0 Ca2 mrebs, CaCl2 was omitted. For Ca
2free Krebs, CaCl2
as omitted, and 2 mM ethylene glycol-bis[-aminoethyl
ther]-N,N,N=, N=-tetraacetic acid (EGTA; Sigma) was
dded. KCl depolarizing solution (16-96 mM) was pre-
ared as normal Krebs but with equimolar substitution of
aCl with KCl. Stock solutions (101 M) of -escin,
iosmin, phenylephrine (PHE), angiotensin II (AngII,
igma), and diltiazem (Calbiochem, La Jolla, Calif) were
repared in distilled water. Other chemicals were of reagent
rade or better.
Animals and tissues. Male Sprague–Dawley rats (12
eeks, 250-300g; Charles River Laboratory, Wilmington,
ass) were housed in the animal facility and maintained on
d libitum standard rat chow and tap water in 12-hour/12-
our light/dark cycle. Rats were euthanized by inhalation
f CO2. The inferior vena cave (IVC) was rapidly excised,
laced in oxygenated Krebs solution, and carefully dis-
ected and cleaned of connective tissue under microscopic
isualization. The IVC was portioned into 3-mm rings in
reparation for isometric contraction experiments. Ex-
reme care was taken throughout the vein isolation, dissec-
ion procedure, and mounting in the tissue bath in order to
inimize injury to the vein wall and endothelium. Using
his careful approach, we have previously shown that ace-
ylcholine causes significant relaxation of IVC segments
recontracted with PHE, indicating that the endothelium
s intact and functional.22 All procedures followed the
ational Institutes of Health guide for the Care of Labo-
atory Animal Welfare Act and the guidelines of the Animal
are and Use Committee at Harvard Medical School.
Isometric contraction. Circular segments of IVC
ere suspended between two stainless-steel hooks; one
ook was fixed at the bottom of a tissue bath, and the other
ook was connected to a Grass force displacement trans-
ucer (FT03; Astro-Med Inc, West Warwick, RI). Vein
egments were stretched under 0.5 g of resting tension and
llowed to equilibrate for 40 min in a tissue bath filled with
0 mL Krebs solution continuously bubbled with 95% O2
% CO2 at 37°C. The changes in isometric contraction/
elaxation were recorded on a Grass polygraph (Model 7D;
stro-Med Inc). Control IVC contraction in response to
6 mM KCl was first elicited. Once the KCl contraction
eached a maximum and a plateau was achieved (within
0-15 minutes), the vein was washed three times in Krebs,
or 10 minutes each. The control contraction to 96 mM
Cl was repeated twice prior to further experimentation.
Escin and diosmin concentration–response curve
nd Ca2-dependent contraction. Following KCl-
nduced control contractions, increasing concentrations of
scin or diosmin (1010 to 104 M) were added, and their
ffect on IVC contraction was measured. In vivo studies in
8 healthy human volunteers have shown that after admin-
stration of an escin 50-mg tablet daily, the average plasma
evels reach 10 ng/mL ( 105 M) at 12 hours and 7
g/mL ( 7 106 M) at 24 hours. Over the course of a
eek, escin plasma levels were maintained at 8 ng/mL
 8 106 M).10 The present experiments demonstrated
easurable effects of escin on vein contraction at 1-, 10-,
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Volume 54, Number 2 Raffetto and Khalil 491and 100-micromolar concentrations. To test for the role of
Ca2 entry from the extracellular space through Ca2
channels, the veins were pretreated with the Ca2 channel
blocker diltiazem (105 M) followed by increasing concen-
trations of escin (1010 to 104 M), and the venous con-
traction was measured. To test for the extracellular
Ca2independent effects and possible intracellular Ca2
release mechanisms, the vein response to increasing con-
centrations of escin or diosmin was measured in Ca2free
(2 mM EGTA) Krebs. To test for extracellular
Ca2dependent effects, IVC segments were pretreated
with escin or diosmin (104 M) in 0 Ca2 Krebs for 5
minutes, then increasing extracellular CaCl2 concentra-
tions (0.1, 0.3, 0.6, 1, 2.5 mM) were added, and the
[Ca2]econtraction relationship was constructed.
Effects of escin and diosmin on PHE, AngII, and
KCl contraction. IVC segments were incubated in nor-
mal Krebs solution containing 2.5 mM Ca2, nontreated
or pretreated with escin or diosmin (104 M) for 2 hours.
The veins were washed with Krebs solution three times for
10 minutes each, then stimulated with PHE (105 M),
AngII (106 M), or KCl (96 mM), and the vein contrac-
tion was measured. These doses of PHE, AngII, and KCl
have previously been shown to produce maximal IVC con-
traction.22,23
Synergistic effects of diosmin. To test if diosmin
potentiates the Ca2dependent mechanisms of VSM
contraction, IVC segments were pretreated with diosmin
(104 M), then subjected to increasing concentrations of
KCl (16-96 mM). To test if diosmin potentiates the effects
of other venotonics, IVC segments were pretreated with
diosmin (104 M) then subjected to increasing concentra-
tions of escin (1010 to 104 M), and the venous contrac-
tion was measured.
Statistical analysis. Each rat IVC produced four cir-
cular segments. One IVC segment was used for each exper-
imental protocol, and the average data from different IVC
segments for each experimental protocol were measured.
The “n” value represented the number of experiments on
different IVC segments from different rats. Vein contrac-
tions in mg/mg tissue weight were presented as means 
SEM (n) and compared using Student’s t test for paired and
unpaired data. Differences were considered statistically sig-
nificant if P 	 .05.
RESULTS
In IVC segments incubated in normal Krebs (2.5 mM
Ca2), escin caused concentration-dependent contraction
reaching a maximum of 104.3  19.6 mg/mg tissue or
48.3  4.4% of control KCl contraction (Figs 1, A and
2, A). The escin-induced contraction was reversible, and
after washing three times with Krebs, the veins returned to
a relaxed state, suggesting that the escin-induced contrac-
tion does not constitute a rigor state. Topical application or
pretreatment of IVC segments with the Ca2 channel
blocker diltiazem (105 M) did not cause significant reduc-
tion in escin-induced contraction (Figs 1, A and 2, A). In
Ca2free (2 mM EGTA) Krebs, escin caused minimal cVC contraction (3.8 2.0 at 104 M; Figs 1,C and 2,A),
upporting that escin-induced contraction is not solely due
o its pore-forming properties and potential loss of intra-
ellular ATP and, consequently, contractile rigor. In com-
arison with escin, increasing concentrations of diosmin
aused a very small vein contraction in normal Krebs solu-
ion (maximum 11.7  1.9 mg/mg tissue or 13.3  3.3%
f control KCl contraction; Figs 1, B and 2, B) and
a2free (2 mM EGTA) Krebs (4.2  2.2 at 104 M;
igs 1, D and 2, B).
We tested the Ca2dependent component of escin
ontraction. In IVC pretreated with escin (104 M) in 0
a2 Krebs, stepwise addition of extracellular CaCl2 (0.1-
.5 mM) caused corresponding increases in contraction
hat reached a maximum of 80.0  11.1 at 2.5 mM CaCl2
Figs 1, E and 2, C). Control experiments in IVC segments
ontreated with escin demonstrated minimal contraction
n response to increasing concentrations of CaCl2 (3.8 
.0 at 2.5mM CaCl2; Fig 2, C). In comparison with escin,
VC segments pretreated with diosmin (104 M) in 0 Ca2
rebs, stepwise addition of extracellular CaCl2 elicited only
very small contraction (1.2  1.2 at 2.5 mM CaCl2; Figs
, F and 2, D).
Because escin and diosmin demonstrated different vein
ontraction profile and Ca2dependent contractile re-
ponses, we tested whether they also differentially affect the
enous contractile response to other vasoconstrictor ago-
ists. In the absence of escin, the IVC demonstrated signif-
cant contraction in response to the -adrenergic agonist
HE (122.5  45.1 at 105 M), AngII (114.2  12.2 at
06 M), and membrane depolarization by 96 mM KCl
221.7  35.4) (Fig 3). In IVC segments pretreated with
scin (104 M) for 2 hours, the PHE, AngII, and KCl-
nduced contraction were significantly reduced (Fig 3). In
ontrast with the experiments with escin, the PHE, AngII,
nd 96 mM KCl-induced contractions were not signifi-
antly different in IVC segments pretreated with diosmin
104 M) as compared with control contractions in the
bsence of diosmin (Fig 3).
Membrane depolarization by KCl is known to stimu-
ate Ca2 entry via voltage-gated Ca2 channels.21 Some
tudies also suggest that KCl may activate Ca2 sensitiza-
ion pathways.24,25 To evaluate possible potentiation and
a2 sensitization effects of diosmin, we tested whether
retreatment with diosmin (104 M) enhances the vein
esponse to increasing concentrations of KCl (16-96 mM).
t KCl concentrations of 24 to 51 mM, diosmin caused a
mall but significant enhancement of vein contraction
Fig 4, A). On the other hand, vein pretreatment with
iosmin (104 M) did not enhance the contractile response
o increasing concentrations of escin (Fig 4, B). In effect, a
ignificant inhibition of contraction to escin (105 M) was
bserved in veins pretreated with diosmin (Fig 4, B).
ISCUSSION
The main findings of the present study are: 1) escin
auses Ca2dependent venous contraction; 2) escin de-
reases contraction to venoconstrictors such as -adrenergic
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August 2011492 Raffetto and Khaliland AngII (AT1R) receptor stimulation, and membrane
depolarization; 3) diosmin does not cause contraction or
enhance contraction to endogenous venoconstrictors such
as PHE and AngII or other venotonics such as escin, but
enhances vein contraction to KCl-induced membrane de-
polarization at low concentrations.
An important property of escin is that it forms small
plasma membrane pores, allowing investigators to examine
various Ca2dependent and Ca2sensitization path-
ways of vascular contraction.10,15-17, 26,27 The present
study demonstrated that escin induced Ca2dependent
venous contraction because: 1) escin contraction was ob-
served in normal Krebs (2.5 mM Ca2) and was signifi-
cantly attenuated in Ca2free Krebs; and 2) increasing
concentrations of extracellular Ca2 caused significant con-
traction in escin-treated IVC, but not in control veins in the
absence of escin. Previous studies have shown that escin-
induced contraction of the rat aorta is reduced by 25% in
endothelium-denuded vessels or in the presence of the
cyclooxygenase inhibitor indomethacin, and suggested a
partial role of a vasoconstrictor prostaglandin-dependent
pathway.15 We should note that, when compared with the
rat aorta, the rat IVC is very delicate, and mechanical
Fig 1. Representative traces of the effect of escin and dio
treated with escin or diosmin (1010 to 104 M) in norm
EGTA) Krebs (C and D). In other experiments, IVC seg
escin (E) or diosmin (F), then increasing concentration
contractile response to Ca2 was observed. Traces are re
min; vertical bar 
 0.5 g.removal of the endothelium often causes injury to the edjacent VSM and considerable reduction in vein contrac-
ion. Although we did not test the effects of escin in
ndothelium-denuded IVC, the potential role of escin-
nduced prostaglandin release needs to be further exam-
ned. It could be argued that the observed escin-induced
ein contraction is solely due to formation of pores in the
lasma membrane, which would allow loss and depletion of
ntracellular ATP and consequently VSM contractile
igor.28,29 If this is the case, then the escin-induced con-
ractile rigor would be difficult to reverse, which is opposite
rom the observed return of the veins to the relaxed state
pon washing with normal Krebs. Also, if escin contraction
s a rigor state due to loss of intracellular ATP, then escin
hould also produce contraction in Ca2free solution.
he observation that escin contraction was almost abol-
shed in IVC incubated in Ca2free Krebs is consistent
ith reports that the contractile response of escin is abol-
shed in a Ca2free perfusion fluid.15 These data indicate
hat escin-induced contraction is not solely due to its pore
orming properties, loss of intracellular ATP, and VSM
ontractile rigor. However, upon the addition of extracel-
ular Ca2 up to 2.5 mM, escin caused contraction of the
VC, suggesting that Ca2 entry from the extracellular
on rat inferior vena cava (IVC). Rat IVC segments were
rebs (2.5 mM Ca2; A and B), or in Ca2free (2 mM
ts incubated in 0 Ca2 Krebs were treated with 104 M
extracellular CaCl2 (0.1-2.5 mM) were added and the
ntative of four to nine experiments. Horizontal bar 
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Volume 54, Number 2 Raffetto and Khalil 493One possibility is that escin may enhance Ca2 entry
through specific Ca2 channels. Ca2 antagonists such as
diltiazem block Ca2 entry through voltage-gated L-type
Ca2 channels.30 The observation that diltiazem did not
significantly affect escin-induced contraction suggests that
escin may not be acting by enhancing Ca2 entry through
L-type Ca2 channels. The data suggest that the mecha-
nism of escin-induced contraction more likely involves
formation of nonspecific membrane pores small enough to
allow Ca2 movement across the plasma membrane, rather
than activation of specific Ca2 channels. However, VSM
also expresses N- and T-type Ca2 channels,31,32 and the
effects of escin on these channels need to be examined in
future studies.
An important finding of this study is that pretreatment
of IVC with escin decreased the contractile response to the
-adrenergic receptor agonist PHE. The decreased PHE
contraction in escin-treated veins may not be due to dam-
age of -adrenergic receptors because: 1) previous studies
demonstrated robust response to PHE in rabbit portal vein
and mesenteric artery permeabilized with escin (75M) for
35 minutes;18,33,34 2) escin decreased another receptor-
Fig 2. Effect of escin and diosmin on rat inferior vena
concentrations (1010 to 104 M) of escin (A) or diosm
diltiazem (105 M), and in Ca2free (2 mM EGTA) Kr
Krebs were either nontreated (control) or treated with 1
tions of extracellular CaCl2 (0.1-2.5 mM) were added an
Data represent the means  SEM (n 
 4-9).mediated contractile response induced by AngII, which is vnown to activate AT1R receptor-mediated signaling path-
ays; and 3) escin decreased the contractile response to
embrane depolarization by KCl, a receptor-independent
esponse that involves Ca2 entry from the extracellular
pace. We have previously shown that matrix metallopro-
einases (MMPs) are expressed in rat IVC and cause mem-
rane hyperpolarization and inhibition of vein contrac-
ion.23 Because MMPs are Ca2dependent, it is likely
hat escin-induced increase in venous Ca2 could activate
MPs, which may in turn cause membrane hyperpolariza-
ion and inhibition of vein contraction. Another possibility
s that prolonged treatment of the rat IVC with escin may
ause structural or chemical changes in the vein that reduce
he vein responsiveness to various contractile stimuli. Fu-
ure histology studies would further examine any potential
henotypic damage following vein treatment with escin.
Escin is a major constituent of horse chestnut seed
xtract that is used clinically to treat chronic venous disor-
ers, including varicose veins, edema, pain, leg fatigue/
eaviness, calf cramps, and itching.12,13 The escin-induced
VC contraction suggests a measurable venotonic effect
hat, in the short term, could be useful in improving the
(IVC). Rat IVC segments were treated with increasing
) in normal Krebs (2.5 mM Ca2), in the presence of
n other experiments, IVC segments incubated in 0 Ca2
escin (C) or diosmin (D), then increasing concentra-
Ca2 concentration-contraction curve was constructed.cava
in (B
ebs. I
04 M
d theenous tone of varicose veins. However, the observed re-
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August 2011494 Raffetto and Khalilduction in the contractile response to endogenous veno-
constrictors in escin-treated veins suggests that the initial
venotonic benefits of escin may be offset in the long term
due to decreased VSM responsiveness to venoconstrictor
stimuli and possible disruption of the normal physiological
vein response to increased sympathetic activity and changes
in the hormone environment during exercise and stress.
Further studies in human veins are needed to determine if
prolonged treatment with escin inhibits the physiological
receptor-mediated signaling pathways and disrupts the
VSM contractile mechanisms.
Diosmin is a flavonoid processed as a micronized puri-
fied flavonoid fraction (Daflon 500). Diosmin has been
promoted for its inhibitory effects on inflammation, im-
proved lymphatic drainage, and venotonic properties, and
is used in the treatment of chronic venous insufficiency and
venous leg ulcers.35,36 Previous studies have suggested that
the vasoconstrictor effects of diosmin involve inhibition of
COMT, decreased metabolism of norepinephrine, and en-
hanced sympathetic activity.19,20 Other studies have dem-
onstrated potentiation effects of diosmin on norepineph-
rine-induced contraction of both human normal saphenous
Fig 3. Effect of escin and diosmin on phenylephrine (PHE), angio-
tensin II (AngII), and depolarization-induced contraction in rat
inferior vena cava (IVC). Rat IVC segments were treated with PHE
(105 M;A), AngII (106 M;B), or 96 mM KCl (C) in the absence
(open bars) or presence of escin (104 M; black bars) or diosmin
(104 M; shaded bars). The contractile response was recorded and
presented as the percentage of control contraction (A, C), or as
mg/mg tissue weight (B). Data represent the means SEM (n

4-19). *Significant P 	 .05.vein and varicose veins in vitro.37 The present study dem- cnstrates that diosmin alone does not cause significant
a2dependent or Ca2independent contraction in
at IVC. Also, pretreatment with diosmin does not enhance
he rat IVC contraction to PHE. The differences in the
esults could be related to the species or vein tissue studied,
r the activator of the adrenergic receptor, where norepi-
ephrine activates -receptors and some -receptors, while
HE is a specific 1-receptor agonist. Future studies
hould compare the effects of diosmin on vein contraction
nduced by different -adrenergic receptor activators, in-
luding epinephrine, norepinephrine, and PHE.
Our experiments with AngII and high concentrations
f KCl supported that diosmin did not potentiate IVC
ontraction. Since various concentrations of KCl cause
arious degrees of membrane depolarization and conse-
uently extracellular Ca2 entry, we explored whether
iosmin potentiates the contractile effects of low KCl con-
ig 4. Effect of diosmin on KCl and escin-induced IVC contrac-
ion. IVC segments were either nontreated (open circles) or pre-
reated with diosmin (104 M; closed circles) then stimulated with
ncreasing concentrations of KCl (16-96 Mm; A) or escin (1010
o 104 M; B) and the contractile response was recorded. Data
epresent the means  SEM (n 
 7-8). *Significant P 	 .05.entrations. Diosmin potentiated KCl-induced contraction
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Volume 54, Number 2 Raffetto and Khalil 495at concentrations 24 to 51 mM. Other studies have shown
that diosmin at 106M concentration enhances Ca2
sensitivity in escin skinned rat femoral vein.16 However, we
were not able to demonstrate any significant contraction
elicited by diosmin at a concentration range of 1010 to
104 M. Also, diosmin at 104 M did not potentiate
escin-induced venous contraction. The difference in the
results could be related to the tissue studied (IVC vs
femoral vein), and the temperature of the bathing medium
(37°C vs 25°C). Other explanations are that diosmin re-
quires specific cofactor(s) to increase venous Ca2 sensitiv-
ity and produce an effective contraction, or that diosmin
itself may need to penetrate the veins in order to sensitize
the VSM cells to Ca2.
Thus, in rat IVC, escin induces extracellular
Ca2dependent contraction that could translate into
measurable venotonic effects, but may also disrupt -
adrenergic and AT1R receptor-mediated pathways, and
depolarization-induced vein contraction. The initial ven-
otonic benefits of escin may be offset by disruption of VSM
response to endogenous venoconstrictors and thereby limit
its long-term therapeutic benefit in varicose veins. The
present ex vivo experiments also demonstrate that diosmin
does not cause venous contraction or potentiate the
venotonic effects of endogenous venoconstrictors or escin,
and its use as venotonic may need to be further evaluated in
carefully designed clinical trials.
Limitations of the present study include the use of rat
veins, the absence of circulating blood, and the concentra-
tions of -adrenergic receptor agonist and AngII that may
exceed the physiological levels. It should be noted that
diosmin has been shown to decrease inflammation in the
microcirculation and to reduce leukocyte activation and the
surface expression of CD62L by neutrophils and mono-
cytes.38-42 Given the ex vivo conditions of the present study
and the absence of circulating cellular elements, the lack of
venotonic effects of diosmin should not minimize other
potential beneficial anti-inflammatory effects of diosmin on
varicose veins in vivo.
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